Direct evidence of the presence of cross-linked Aβ dimers in the brains of Alzheimer's disease patients by Vázquez de la Torre Cervera, Aurelio et al.
 
 
Direct Evidence of the Presence of Cross-Linked Aβ Dimers in the Brains of 
Alzheimer’s Disease Patients 
 
 
Aurelio Vázquez de la Torre,1# Marina Gay,2# Sílvia Vilaprinyó-Pascual,1 Roberta 
Mazzucato,1 Montserrat Serra-Batiste,1 Marta Vilaseca,2 Natàlia Carulla1,3* 
 
 
 
1Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of 
Science and Technology (BIST), Baldiri Reixac 10, 08028 Barcelona, Spain 
2Mass Spectrometry and Proteomics Core Facility, Institute for Research in 
Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology 
(BIST), Baldiri Reixac 10, Barcelona 08028, Spain 
3CBMN (UMR 5248), University of Bordeaux – CNRS – IPB, Institut Européen 
de Chimie et Biologie, 2 rue Escarpit, 33600, Pessac, France 
 
Both authors have contributed equally to this work 
*Corresponding author: 
Natàlia Carulla, 2 rue Escarpit, 33600, Pessac, France, telephone: +33 (0) 5 4000 
3008, e-mail: n.carulla@iecb.u-bordeaux.fr 
  
  
 
Abstract 
Brain-derived amyloid-β (Aβ) dimers are associated with Alzheimer´s disease 
(AD). However, their covalent nature remains controversial. This feature is relevant, 
as a covalent cross-link would make brain-derived dimers (brain dimers) more 
synaptotoxic than Aβ monomers and would make them suitable candidates for 
biomarker development. To resolve this controversy, we here present a three-step 
approach. First, we validated a type of synthetic cross-linked Aβ (CL Aβ) dimers, 
obtained by means of the photo-induced cross-linking of unmodified proteins 
(PICUP) reaction, as well-defined mimics of putative brain CL Aβ dimers. Second, 
we used these PICUP CL Aβ dimers as standards to improve the isolation of brain Aβ 
dimers and to develop state-of-the-art mass spectrometry (MS) strategies to allow 
their characterization. Third, we applied these MS methods to the analysis of brain Aβ 
dimer samples allowing the detection of the CL [Aβ(6-16)]2 peptide comprising a 
dityrosine cross-link. This result demonstrates the presence of CL Aβ dimers in the 
brains of patients with AD and opens up avenues for establishing new therapeutic 
targets and developing novel biomarkers for this disease. 
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Introduction 
Amyloid-β (Aβ) oligomers are considered the pathogenic molecular form of Aβ in 
Alzheimer’s disease (AD). In this regard, many laboratories worldwide have 
channeled efforts to either prepare Aβ oligomers using a range of in vitro conditions1-5 
or to isolate them from brain tissue.6,7 As a result of these works, many Aβ oligomer 
forms have been put forward as the pathogenic form of Aβ in AD. However, 
establishing which of them is the most pathophysiologically relevant is still a matter 
of debate.8 Of the Aβ oligomers described to date, only Aβ dimers have been isolated 
from the cerebral cortex of subjects with AD. Notably, brain-derived Aβ dimers 
(brain Aβ dimers) impair synapse structure and function,7 induce neurofibrillary 
degeneration,9 and are associated with this disorder.10,11 On the basis of these 
observations, brain Aβ dimers have been proposed as the most pathophysiological 
relevant material for further pathway analysis and for the preclinical validation of 
agents designed to neutralize Aβ aggregates.7  
However, if brain Aβ dimers are to be targeted, they first need to be characterized. 
In this context, one of the biggest challenges has been to establish whether these 
dimers are non-covalently or covalently linked. Settling this question is critical 
because work with synthetic cross-linked Aβ (CL Aβ) dimers has revealed that the 
cross-link leads to the formation of soluble synaptotoxic assemblies that persist for 
longer periods than those formed by monomeric Aβ.12,13 Moreover, demonstration 
that brain Aβ dimers are cross-linked would facilitate their isolation and manipulation 
from biological fluids, thus making them suitable candidates for biomarker 
development.  
Two premises support the hypothesis that brain Aβ dimers are cross-linked. First, 
previous studies have shown that dimers isolated from AD brain tissue are highly 
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resistant to denaturing conditions.7,10,14 Second, other studies have reported that cross-
linking occurs as a result of oxidative stress, which has also been described as an early 
event in AD15. In this context, immunohistochemical detection of dityrosine (Y-Y) 
cross-linking has been reported in brain regions enriched in amyloid plaques and in 
the cerebrospinal fluid (CSF) of AD patients.16 On the basis of these observations, the 
formation of a Y-Y cross-link between two Aβ molecules has been proposed. 
However, in spite of these premises, no direct evidence in support of the covalent 
nature of brain Aβ dimers has been reported. 
The lack of such evidence could be taken to mean that brain Aβ dimers are non-
covalent; however, aspects such as their limited sample availability and/or their 
propensity to aggregate encumber their isolation and subsequent characterization. 
Here we present a three-step approach to overcome these limitations. First, we 
established the cross-linked positions in synthetic CL Aβ dimers obtained by means 
of the photo-induced cross-linking of unmodified proteins (PICUP) reaction.3,17,18 
These dimers are mainly cross-linked through a Y-Y bond, involving the only 
tyrosine residue present in the Aβ sequence, which is tyrosine 10 (Y10). Since this 
type of cross-link is the same as that proposed to be formed in the brain under 
oxidative stress, we considered PICUP CL Aβ dimers as well-defined synthetic 
mimics of putative brain CL Aβ dimers. Second, we used these PICUP CL Aβ dimers 
to improve their isolation and to characterize them using state-of-the-art bottom-up 
mass spectrometry (MS). Third, we applied the optimized isolation and MS 
characterization strategies to analyze Aβ dimer samples obtained from brain tissue of 
AD patients. This approach provided unequivocal evidence of the presence of CL Aβ 
dimers in the brains of patients with this condition. 
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Experimental Section 
GdnHSCN-SEC-WB analysis of synthetic Aβ samples 
We worked with low molecular weight (LMW), fibril, and PICUP CL Aβ(1-40) 
and Aβ(1-42) samples, prepared as detailed in the SI Experimental Section 
“Preparation of synthetic Aβ samples”. Appropriate volumes of these samples, 
corresponding to 248.9 µg of Aβ(1-40) or Aβ(1-42), were freeze-dried and 
resuspended in 29.3 µL of 6.8 M guanidine thiocyanate (GdnHSCN) (8.5 mg/mL Aβ). 
They were then sonicated for 5 min and diluted with 20 µL of H2O to 4 M GdnHSCN 
(5 mg/mL Aβ). The samples were passed through a 0.45-µm PVDF centrifugal filter 
(Millipore) and injected into two columns in series—a Superdex 75 10/300 GL-
Superdex 200 10/300 GL (GE Healthcare). The columns were equilibrated in 10 mM 
ammonium acetate pH 8.5, and the samples were eluted into 1-mL fractions at 4ºC at 
a flow rate of 0.5 mL/min. The concentration of synthetic Aβ species after Size 
Exclusion Chromatography (SEC) was determined through a UV detector at 220 nm. 
A calibration curve had been previously generated from known amounts of Aβ 
species assessed by reversed-phase high performance liquid chromatography (RP-
HPLC).18 Next, 800 µL of each fraction was taken and stored at -80°C. The remaining 
200 µL were aliquoted in 10-µL fractions, which was the minimum amount amenable 
for aliquot preparation. Afterwards the required volume, such that the dimer fraction 
corresponded to ~10 ng, was taken for all the SEC fractions. It was then lyophilized, 
reconstituted in 20 µL of 4X Sample Buffer (4X SB), heated at 95°C for 5 min, and 
analyzed by WB using monoclonal Aβ antibodies 6E10 (1:5000) and 4G8 (1:5000). 
To calibrate the tandem Superdex 75-Superdex 200 10/300 GL columns, the 
following standards were used: β-amilase (200 kDa); bovine serum albumin (BSA) 
(67 kDa); carbonic anhydrase (29 kDa); and cytochrome C (12.4 kDa). 
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GdnHSCN-SEC-WB analysis of brain Aβ samples  
Brain samples were obtained from the Brain Banks of the Institute of 
Neuropathology of the IDIBELL-University Hospital Bellvitge and of the Hospital 
Clínic-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), both in 
Barcelona, Spain. The study was carried out in accordance to the Spanish Legislation 
on this matter (Real Decreto Biobanco 1716/2011) and the approval of the local 
IDIBELL-University Hospital Bellvitge and IDIBAPS ethics committees. Brain 
donors and/or relatives gave their written informed consent for the use of brain tissue 
for research purposes. Brain samples from AD patients and those from 
neuropathological controls without a history of dementia, psychiatric or neurological 
diseases were processed between 2-10 h after death of individuals and characterized 
following CERAD criteria19 and the Braak&Braak scale.20,21 Detailed characteristics 
of patients are provided in Table S2. The GdnHSCN extract was prepared as detailed 
in the SI Experimental Section “Preparation of human brain samples”. 300 µL of 6.8 
M GdnHSCN extract, corresponding to the insoluble fraction derived from sequential 
extractions of 0.6 g of brain tissue, were diluted to 4 M GdnHSCN by adding 210 µL 
of H2O. The extract was then clarified by centrifugation at 175,000 g and 4°C in a 
SW55Ti rotor (Beckman Coulter Inc. Brea, CA, USA) for 30 min. The supernatant 
was then passed through a 0.45-µm PVDF centrifugal filter (Millipore Corp, Billerica, 
MA, USA). The resulting solution was injected and eluted using the same SEC 
columns and conditions used to analyze synthetic Aβ samples. Next, 800 µL of the 
fractions eluting as dimers were taken and stored at -80ºC for bottom-up MS 
characterization. The remaining 200 µL was aliquoted into 45-µL fractions and then 
lyophilized, reconstituted in 20 µL of 4X SB, heated at 95°C for 5 min, and used for 
WB analysis with monoclonal Aβ antibodies 6E10 (1:5000) and 4G8 (1:5000). SEC 
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fractions containing brain Aβ dimers were quantified by reference to known amounts 
of PICUP CL Aβ(1-40) dimers (Figure S1). From 0.6 g of brain tissue, we obtained 
two 1-mL fractions eluting at 24 and 25 mL, each containing the highest 
concentration of dimers, corresponding to 555 ng and 222 ng, respectively.  
Identification of CL peptides and positions in PICUP CL Aβ(1-40) dimers  
Sample digestion and LC-MS/MS analysis. 2 µg of PICUP CL Aβ(1-40) dimers 
prepared and purified by SEC as previously described18 were lyophilized, 
resuspended in 50 mM ammonium carbonate at pH 7.8, and digested in the presence 
of 10% weight of trypsin or GluC at 37°C overnight. Afterwards, digestions were 
quenched by reaching a final concentration of 1% formic acid (FA), and 1 pmol of the 
resulting peptide mixtures was loaded onto a nanoscale liquid chromatography system 
coupled to tandem mass spectrometry (nano-LC-MS/MS). A full description of the 
nano-LC-MS/MS analysis used to study the digested samples is provided in the SI 
Experimental Section “nanoLC-MS/MS conditions for the identification of cross-
linked peptides and positions in PICUP CL Aβ(1-40) dimers”. 
Data processing. To identify cross-linked peptides and determine cross-link 
positions, all data were processed using StavroX v3.6.2,22 kindly provided by Prof. Dr. 
Andrea Sinz and Dr. Michael Götze (Martin-Luther University, Halle-Wittenberg, 
Germany). Searches were run against a FASTA database, which contained the Aβ(1-
40) sequence. Search parameters included trypsin and GluC enzyme, allowing for two 
missed cleavage sites, and for methionine oxidation as a dynamic modification. Given 
the proposed mechanism for PICUP described in the main text, the following cross-
linking positions were considered: Y-Y, tyrosine-serine (Y-S), tyrosine-lysine (Y-K), 
and tyrosine-histidine (Y-H). Peptide mass tolerance was set at 10 ppm and MS/MS 
tolerance at 20 ppm. To establish the position of the cross-link, peptide spectrum 
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matches (PSMs) were filtered with a false discovery rate (FDR) < 1% and 
subsequently validated manually (Table S1). 
Bottom-up MS proteomic identification of cross-linked Aβ peptide [Aβ(6-16)]2 
within dimer fractions 
SEC fractions corresponding to either PICUP CL Aβ(1-40) dimers or to brain Aβ 
dimers were used. For the former, we analyzed 3 technical replicates, while for the 
latter, we worked with 2 biological replicates, AD1 and AD2 (Table S2). As synthetic 
samples, a volume corresponding to 500 ng of PICUP CL Aβ(1-40) dimers was used. 
As brain samples, we worked with 650-800 µL, containing between 144 and 444 ng 
of brain Aβ dimers (Figure S1). The latter were immunoprecipitated as described in 
the SI Experimental Section “Immunoprecipitation of brain Aβ dimer fractions”. 
Afterwards, both synthetic and brain samples were resuspended in 40 µL of 50 mM 
NH4HCO3 pH 7.8 and digested with 100 ng of trypsin at 37ºC overnight. Digestions 
were quenched by reaching a final concentration of 1% FA. Samples were dried in a 
speed-vac and resuspended with 10 µL of 0.1% TFA. They were then analyzed using 
the nano-LC-MS/MS system described in the Experimental Section “nanoLC-MS/MS 
conditions for bottom-up MS proteomic identification of cross-linked Aβ peptide 
[Aβ(6-16)]2”. 
Results 
PICUP CL Aβ dimers are mainly cross-linked through Y10-Y10 
The PICUP reaction has been widely used to prepare CL Aβ oligomers formed 
during early stages of Aβ aggregation.3,18 It involves the photo-excitation of 
ruthenium(II) tris-bipyridyl complex, Ru(II)bpy3, in the presence of persulfate to 
generate Ru(III) and a sulfate radical (Figure S2a). Ru(III) is a potent one-electron 
oxidant with a strong propensity to generate a radical. Within the Aβ sequence, the 
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side chain of Y10 is the most reactive site to stabilize a radical. Based on the proposed 
PICUP mechanism,3,23 the resultant Y radical could proceed to form cross-linked 
products by reacting with another Y residue (Figure S2b, right). Alternatively, a 
nearby reducing side chain, such as those of cysteine (C), serine (S), lysine (K), or 
histidine (H), could also attack the radical (Figure S2b, left). Given these mechanistic 
considerations, and since C is not present in the sequence of Aβ, the PICUP reaction 
could lead to the formation of a cross-link between the following amino acid pairs: Y-
Y, Y-S, Y-K, and Y-H. However, in spite of these proposed mechanistic 
considerations, the actual cross-link positions within PICUP CL Aβ dimers have not 
been established. To elucidate whether cross-links formed by means of the PICUP 
reaction are physiologically relevant, such as Y10-Y10,16,24,25 and to facilitate access 
to well-defined synthetic mimics of putative brain CL Aβ dimers, we proceeded to 
characterize the cross-link positions within PICUP CL Aβ dimers.  
To this end, we first prepared PICUP CL Aβ(1-40) dimers, as recently described.18 
Next, we subjected them to enzymatic digestion using trypsin and GluC to obtain 
cross-linked peptides. The latter were subsequently analyzed by nanoLC-MS/MS to 
identify them and to determine the position of the cross-link. Five distinct cross-
linked peptides were identified: three homodimers, [Aβ(4-11)]2, [Aβ(6-16)]2, and 
[Aβ(1-11)]2, and two heterodimers, Aβ(4-11)-Aβ(1-11) and Aβ(6-16)-Aβ(1-16) 
(Table S1). Notably, all of them corresponded to the N-terminal part of Aβ and 
contained Y10 in their sequence. To analyze the LC-MS/MS data, we used StavroX, a 
software package dedicated to identifying cross-link positions in peptides, and 
considered the four potential positions proposed for the PICUP mechanism Y-Y, Y-S, 
Y-K, and Y-H. This analysis revealed that in 267 out of 268 MS/MS spectra, 
corresponding to the five cross-linked peptides identified, Y10-Y10 was the site with 
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the highest probability of holding the cross-link (Table S1, Figure 1a,c and Figures 
S3-S6). Only in two spectra obtained for [Aβ(6-16)]2, one identified by the software 
and the other after manual validation of all the spectra, Y10-S8 was identified with 
the highest probability. In these two spectra, the MS/MS fragment y7α2+ 470.741, 
specific for Y10-S8 and not compatible with Y10-Y10 was detected (Table S1 and 
Fig. 1b,d). Y10-Y10 has been proposed to form within brain Aβ dimers in AD brains 
as a result of oxidative stress.16,24,25 Therefore, the finding that in most of the MS/MS 
spectra corresponding to the five CL Aβ peptides (266 out of 268) derived from 
PICUP CL Aβ(1-40) dimers, the highest probability for the cross-link position was 
assigned to Y10-Y10, validates the use of PICUP CL Aβ(1-40) dimers as well-
defined mimics of putative brain CL Aβ dimers. 
PICUP CL Aβ dimers as standards to improve CL Aβ dimer isolation  
Next, we used PICUP CL Aβ dimers as standards to establish biochemical tools to 
improve their isolation. In this regard, we took advantage of our recently reported 
strategy to purify PICUP CL Aβ oligomers of defined order, including dimers, trimers, 
and tetramers.18 This strategy, referred to as GdnHSCN coupled to SEC (GdnHSCN-
SEC), is based on two steps. The first involves the use of 6.8 M GdnHSCN, a strong 
disaggregating treatment, to break all non-covalent Aβ-Aβ interactions, such that only 
covalent CL Aβ oligomers formed during the cross-linking reaction are preserved. In 
the second step, SEC is used to fractionate CL Aβ oligomers on the basis of size. This 
step is carried out at 4°C and using 10 mM ammonium acetate at pH 8.5 as elution 
buffer to prevent the aggregation of the samples during fractionation.7 When PICUP 
CL Aβ(1-40) and Aβ(1-42) samples were studied using this strategy (Figure S7a and 
Figure 2a), four peaks were detected in the SEC chromatogram. On the basis of ion 
mobility coupled to mass spectrometry (IM-MS), these peaks had previously been 
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assigned to monomers and cross-linked dimers, trimers, and tetramers.18 Next, to 
confirm that indeed 6.8 M GdnHSCN was able to break non-covalent Aβ aggregates 
into their constituent monomers and that the conditions used for SEC analysis 
prevented subsequent monomer aggregation, we carried out two additional controls. 
The first one involved submitting LMW Aβ(1-40) and Aβ(1-42) samples to 
GdnHSCN-SEC analysis (Figure S7c and Figure 2c). LMW corresponds to the lowest 
aggregation state of Aβ, which comprises monomers in rapid equilibrium with low 
order non-covalent oligomers. The second control involved subjecting synthetic 
Aβ(1-40) and Aβ(1-42) fibrils (Figure S8) to GdnHSCN-SEC analysis (Figure S7e 
and Figure 2e). In both cases, a single peak eluting with the same retention volume as 
monomeric Aβ was detected. These results indicate that this GdnHSCN-SEC strategy 
is a reliable way to break Aβ aggregates into their constituent covalent units and to 
prevent their further aggregation during SEC fractionation. 
Next, to make the GdnHSCN-SEC strategy applicable to the analysis of brain 
samples, expected to contain low amounts of Aβ, we incorporated western blot (WB) 
to the overall sample analysis. Thus, synthetic samples obtained after GdnHSCN-SEC 
were subsequently analyzed by WB (Figure S7b,d,f and Figure 2b,d,f). The 
aggregation state of Aβ(1-40) samples detected by WB was the same as that 
determined by SEC (Figure S7b,d,f). However, the aggregation state of the Aβ(1-42) 
samples identified by WB sometimes differed from that determined by SEC (Figure 
2b,d,f). For example, Aβ(1-42) monomers obtained after GdnHSCN-SEC ran 
exclusively as monomers (Figure 2d) or either as monomers and dimers (Figure 2b,f). 
SDS has been reported to affect the aggregation state of Aβ(1-42).18,26 In this context, 
various factors could contribute to the observed anomalous behavior of Aβ(1-42) 
monomers, including the reconstitution process of the lyophilized Aβ samples in SDS 
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and/or the ratio of Aβ(1-42) to SDS. On the basis of these results, we decided to use 
only WB to select fractions for subsequent analysis but not to establish the 
aggregation state of a given sample. In summary, the results obtained by applying the 
GdnHSCN-SEC strategy to distinct synthetic Aβ samples, involving different degrees 
of covalent cross-linking and non-covalent self-assembly, indicate that this strategy is 
a reliable way to break and fractionate Aβ aggregates into their constituent covalent 
units. Subsequent analysis by WB allows the selection of fractions for further 
characterization. 
Brain Aβ dimers are isolated from the brains of patients with AD 
The solubilization of plaque cores using 6.8 M GdnHSCN has been reported.27 
Therefore, we envisioned that the above GdnHSCN-SEC-WB protocol could be 
extended to the isolation of putative brain CL Aβ dimers. Previous studies based on 
the isolation and characterization of such dimers in the human brain relied on 
extracting soluble, membrane-associated, and insoluble fractions by sequential 
centrifugation of brain homogenates obtained from humans neuropathologically 
diagnosed with AD.7 Of these three extracts, brain Aβ dimers were found to be most 
abundant in the insoluble fraction.10,11 Since these dimers impair synapse function in 
the same manner as those obtained directly from the soluble fraction,7 we chose to 
work with the insoluble fraction and thus have access to larger amounts of dimers. 
Accordingly, to establish the presence of CL Aβ dimers in AD brains, we carried out 
serial extractions of brain tissue from AD patients and analyzed the insoluble fraction, 
rich in Aβ plaques, using the GdnHSCN-SEC-WB strategy (Figure 2g,h) previously 
applied to synthetic samples. WB analysis of the SEC fractions revealed bands 
corresponding to Aβ monomers, dimers and trimers (Figure 2h). The latter had 
resisted the strong disaggregating treatment and eluted in the same SEC volume as 
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their synthetic cross-linked counterparts (compare Figure 2h to 2b), thereby 
suggesting that CL Aβ oligomers were present in this brain sample. The resistance of 
brain Aβ dimers to strong denaturants had already been reported.14 Specifically, the 
use of denaturants such as 6M GdnHCl, 88% formic acid and 2 M thiourea/6M urea 
had already been used coupled to SEC fractionation to obtain brain Aβ dimers. 
Starting from 0.6 g of brain tissue and using the GdnHSCN-SEC strategy, we 
obtained two fractions, eluting at 24 and 25 mL in SEC, with the highest amounts of 
brain Aβ dimers, each containing 555 ng and 222 ng, respectively (Figure S1). 
Following WB analysis, we observed that, compared to brain monomeric Aβ, brain 
Aβ dimers were more strongly immunodetected by 4G8 (residues 17-24) than by 
6E10 (residues 3-8) antibodies (Figure 2h). This observation is also made when 
comparing synthetic Aβ monomers with PICUP CL Aβ dimers (Figure 2b). The lower 
immunoreactivity of 6E10 for PICUP CL Aβ dimers relative to synthetic Aβ 
monomers could be explained by the presence of the Y10-Y10 cross-link within 
synthetic dimer samples near the 6E10 epitope (Figure 2b). The observation of the 
same behavior for the brain sample could be taken as an indication that brain Aβ 
dimers also comprise a cross-link near the 6E10 epitope (Figure 2h). The higher 
immunoreactivity of 4G8 for brain Aβ dimers relative to brain Aβ monomers has 
already been described previously14. Although in the WBs shown in Figure 2h, it 
appears that 4G8 does not detect brain monomeric Aβ, 4G8 does recognize it when 
using a lower antibody dilution at the expense of losing resolution for brain dimer 
bands (Figure S9).  
Next, to establish whether brain Aβ dimers were present during the different stages 
of AD, we analyzed brain samples from four individuals: three pathologically 
characterized to have different amounts of Aβ burden and one young non-AD control 
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(Table S2). We carried out fractionation of brain extracts of the frontal/parietal 
cortices of the four subjects and analyzed the insoluble pellet, rich in Aβ plaques, 
using the GdnHSCN-SEC strategy. Afterwards, we used WB to analyze SEC 
fractions eluting at the same volume as synthetic Aβ monomers and PICUP CL Aβ 
dimers (Figure 3 and Figure S10). This analysis reproduced previous results in the 
literature7 and showed that all the samples, except those corresponding to the young 
non-AD control, contained monomeric Aβ and Aβ dimers. In the literature, SDS-
PAGE bands running as Aβ dimers have been assigned to N-terminal extended (NTE) 
Aβ forms28,29. At this point of the investigation, we addressed this possibility using 
cyanogen bromide (CNBr) (Figure S11). These experiments allowed us to establish 
that the species eluting as Aβ dimers in our SEC experiments were not NTE Aβ forms.  
The presence of CL Aβ dimers in the brains of patients with AD is confirmed by 
bottom-up proteomics 
Next, to obtain direct evidence of the covalent nature of the isolated brain Aβ 
dimers, we used high-resolution MS through bottom-up proteomics. To this end, we 
first enriched SEC fractions eluting as dimers by immunoprecipitation with 4G8 
antibody. The antibody was chosen on the basis of previous results showing that 4G8 
shows better immunodetection performance for Aβ dimers than 6E10 (Figure S7b 
Figure 2b and 2h). Afterwards, brain Aβ dimer samples were trypsin-digested and 
subsequently analyzed by nanoLC-MS/MS. If brain Aβ dimers were cross-linked, this 
approach should allow us to detect CL peptides encompassing parts of the dimer 
sequence. One of the most abundant trypsin cross-linked peptide identified within 
PICUP CL Aβ(1-40) dimers was [Aβ(6-16)]2 (Table S1 and Figure 1). This peptide 
includes the Y10-Y10 cross-link proposed to occur in an AD brain as a result of 
oxidative stress.3,17,18 Moreover, taking into account the diversity of Aβ sequences in 
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the brain and reports describing a number of N-terminally truncated Aβ forms,30-32 we 
envisioned that the detection of [Aβ(6-16)]2 peptide in brain samples was a solid 
strategy through which to obtain direct evidence of the presence of CL Aβ dimers in 
the brain. 
However, before analyzing immunoprecipitated brain Aβ dimer samples, we 
optimized the nanoLC-MS/MS strategy by working with PICUP CL Aβ(1-40) dimers. 
First, we optimized the LC step. Previous analysis of the cross-link position in the 
synthetic dimers was done using a silica based-C18 chromatographic column, in 
which the [Aβ(6-16)]2 peptide eluted as a broad peak. Given that we expected brain 
Aβ dimers to be of low abundance in the brain, we worked to increase the sensitivity 
of our LC step. To this end, we used an ethylene bridge hybrid (BEH) C18 column, 
under which the [Aβ(6-16)]2 peptide eluted as a narrow peak with a width-at-half-
height of 0.05 min. Afterwards, we set up a targeted proteomics approach based on 
parallel reaction monitoring (PRM) to increase sensitivity. In this approach, a specific 
precursor ion is selected, and the full MS/MS spectra is monitored over the whole 
chromatogram. Specifically, we selected the most abundant + 5 charge state of the 
[Aβ(6-16)]2 peptide as the precursor ion, m/z 534.8444 and monitored the full 
MS/MS spectra (Figure 4a,b,e,f-top). Analysis of the 2267 MS/MS spectra obtained 
for the PICUP CL Aβ(1-40) dimer sample using StavroX revealed Y10-Y10 as the 
site with the highest probability for the cross-link position (Table S3, Figure 4d,h-top). 
No fragment ion characteristic for Y10-S8 was detected in any of the spectra recorded. 
This finding was attributed to its low abundance compared to Y10-Y10 and to the use 
of different chromatographic conditions.  
Next, we analyzed IP-brain Aβ dimer samples corresponding to AD1 and AD2 
patients (Table S2) using the optimized nano-LC-MS/MS method. Notably, the same 
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precursor ion and MS/MS spectrum, as that detected for trypsin digested PICUP CL 
Aβ40 dimer samples, were detected in both brain Aβ dimer samples (Figure 4a,b,e,f-
bottom mirror and Figure S12). To further compare the MS/MS spectra between 
synthetic and brain dimer samples, we selected four characteristic MS/MS transitions 
for the [Aβ(6-16)]2 peptide, namely b2+ 253.093, y52+ 324.682, b104+ 631.775, and b63+ 
674.949. The same retention time and relative intensity was detected for the selected 
MS/MS transitions when comparing those obtained for PICUP CL Aβ(1-40) dimer 
samples with those obtained for both brain dimer fractions (Figure 4c,g). Analysis of 
the 119 MS/MS spectra obtained for sample AD2 and of the 11 MS/MS spectra for 
sample AD1 (Table S3) using StavroX revealed Y10-Y10 as the site with the highest 
probability of holding the cross-link in the brain Aβ dimer samples (Figure 4d,h-
bottom). All together, these results show that the [Aβ(6-16)]2 peptide comprising a 
cross-link between Y10-Y10 is present in Aβ dimer fractions from the brains of AD 
patients, thus demonstrating the presence of CL Aβ dimers in the brains of these 
patients.  
Discussion 
Throughout this work, we have resolved one of the most controversial questions 
posed in the literature regarding the nature of brain Aβ dimers.7,12,13,16 We have 
unequivocally established that they are cross-linked. This conclusion has been 
achieved by first using the GdnSCN-SEC-WB protocol to isolate brain Aβ dimers 
(Figure 2h). Secondly, a bottom-up MS analysis of brain Aβ dimer fractions led to the 
detection of the [Aβ(6-16)]2 CL peptide comprising a cross-link between Y10-Y10 
(Figure 4). This peptide is characteristic of a CL Aβ dimer sequence providing the 
first direct evidence of the presence of CL Aβ dimers in the brains of patients with 
AD.  
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In the brain, covalent dimers have been proposed to form in two ways, namely via 
the generation of an isopeptide bond between glutamine (Q) and K mediated by 
transglutaminase33 or via phenolic coupling of two Y residues mediated by oxidative 
stress.16,24,25 Taking into account these two possibilities for in vivo cross-linking, 
various synthetic Aβ dimers have been proposed as mimics of brain ones. Early work 
by others used crude mixtures containing both CL and non-CL species, also lacking 
definition of the aggregation state and the site of cross-linking.33-35 Later on, dimers 
were formed by the substitution of serine 26 (S26) by cysteine and subsequent 
disulfide bond formation, [Aβ(M1-40)S26C]2.36 However, since [Aβ(M1-40)S26C]2 
lacks biological relevance, other more relevant synthetic dimers have been produced 
and studied, including [Aβ(1-40)]2Y-Y,12 [Aβ(M1-40)]2Y-Y,37 [Aβ(M1-42)]2Y-Y, 
and [Aβ(M1-42)]2Q-K.13 The biological relevance of PICUP CL Aβ oligomers has 
been put into question due to the non-physiological conditions associated with the 
PICUP chemistry. To address this issue, an alternative Copper and Hydrogen 
Peroxide Induced Cross-Linking of Unmodified Proteins (CHIPUP), which utilizes 
naturally occurring divalent copper ions, hydrogen peroxide and does not require 
photo activation, was developed.38 Notably, the oligomer distribution and the 
properties of the resulting oligomers obtained by CHICUP were found to be similar to 
those obtained by PICUP. This observation suggested that although the reagents used 
in the PICUP reaction were not physiological, they promoted the formation of the 
same intermediates and products as those formed during oxidative stress conditions. 
Our results provide direct evidence to support this suggestion. Firstly, both PICUP CL 
Aβ dimers and brain ones are more strongly immunodetected by 4G8 (residues 17-24) 
than by 6E10 (residues 3-8) (Figure 2b and 2h), an effect most likely due to the 
presence of the Y10-Y10 cross-link in both samples. Secondly, both dimers contain 
 
the CL [Aβ(6-16)]2 peptide in their sequences (Figure 4). Thirdly, for both dimers, 
analysis of the MS/MS spectra obtained from the [Aβ(6-16)]2 peptide assigned Y10-
Y10 as the highest probability for the cross-link to be (Figure 4 and Tables S1 and S3). 
On the basis of these results, we propose that PICUP CL Aβ dimers are well-defined 
mimics of brain ones. 
The aggregation properties of synthetic covalent dimers such as [Aβ(1-40)]2Y-Y,12 
[Aβ(M1-40)]Y-Y,37 [Aβ(M1-42)]Y-Y, and [Aβ(M1-42)]Q-K13 have been examined. 
These studies revealed that the starting dimers lack a defined structure but that they all 
populate bioactive soluble assemblies for longer periods than the Aβ monomer.36,37,39 
Since the soluble assemblies that these synthetic dimers populate inhibit synaptic 
plasticity,37 the authors of those studies proposed that the link between Aβ dimers and 
AD results from the ability of these dimers to further assemble and form synaptotoxic 
assemblies that persist for longer periods than those formed by Aβ monomers. Given 
our findings demonstrating the presence of CL Aβ dimers in the brains of AD patients, 
the ability of synthetic CL Aβ dimers to further assemble and form synaptotoxic 
assemblies becomes relevant in the context of AD, thus revealing CL Aβ dimers and 
the assemblies they form as potential new targets in the treatment of AD. 
Finally, there is concern that the buffers used during the isolation and manipulation 
of Aβ oligomers from biological fluids can affect their aggregation state. The finding 
that CL Aβ dimers are present in the brains of patients with AD is an important step in 
the field of biomarker development, as the covalent nature of these samples will allow 
their manipulation under strong denaturing conditions without disruption of their 
oligomerization state. Of note, the LC-targeted MS/MS method developed throughout 
this work could be extended to future studies designed to assess the potential of brain 
CL Aβ dimers as new AD biomarkers. The potential of CL Aβ dimers as biomarkers 
 
of AD is especially relevant since both Aβ and dityrosine have been detected in the 
CSF of patients with this disease16 and CSF samples from patients containing soluble 
Aβ dimers disrupt synaptic plasticity.40 In conclusion, here we provide unequivocal 
evidence of the presence of CL Aβ dimers in the brains of AD patients, thus opening 
up new avenues for the establishment of therapeutic targets and biomarkers for the 
treatment and diagnosis of this disease. 
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Figures 
 
Figure 1. Identification of the CL positions within the [Aβ(6-16)]2 peptide obtained 
after trypsin digestion of PICUP CL Aβ(1-40) dimer. (a, b) Annotated MS/MS 
spectra, selecting the +5 charge state (m/z 534.8444) of [Aβ(6-16)]2 as precursor ion 
for CID fragmentation on a Fusion Lumos Orbitrap, for (a) a representative spectrum, 
out of the 75 detected (a total of 77 measured), consistent with Y10-Y10 and (b) a 
representative spectrum, out of the 2 detected (a total of 77 measured), consistent with 
Y10-S8. The MS/MS fragment ion, y7α2+ 470.741, specific for Y10-S8 and not 
compatible with Y10-Y10 is shown circled. (c, d) Assignment of the fragment ions 
detected in MS/MS spectra shown in a for c and in b for d analyzed by StavroX, on 
the peptide sequence. We named the produced fragment ions containing both the 
cross-link and the two peptide chains using the Schilling nomenclature,42 which 
designates the longer chain as α and the shorter as β. However, in cases when due to 
the symmetry of the CL peptides, the fragment ions could be derived indistinctively 
from either chain, the α and β label was removed for clarity. 
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Figure 2. CL Aβ dimers can be isolated by SEC after a harsh disaggregation step. 
Application of the GdnHSCN-SEC strategy to the analysis of (a) a PICUP CL Aβ(1-
42) sample, (c) a LMW Aβ(1-42) sample, (e) an Aβ(1-42) fibril sample, and (g) the 
insoluble fraction of an AD brain. WB analysis of SEC fractions obtained after 
GdnHSCN-SEC analysis of (b) a PICUP CL Aβ(1-42) sample, (d) a LMW Aβ(1-42) 
sample, (f) an Aβ(1-42) fibril sample, and (h) the insoluble fraction of an AD brain. 
 
Samples were blotted with either 6E10 or 4G8 antibodies. M = monomers, D = 
dimers, Tr = trimers, Te = tetramers. 
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Figure 3. Brain Aβ dimers are detected in the brains of individuals with varying 
degrees of Aβ burden. The insoluble fraction corresponding to brain homogenates of 
individuals with distinct degrees of Aβ burden (Table S2) were analyzed using the 
GndHSCN-SEC strategy. SEC fractions eluting as (a) brain Aβ monomers and (b) 
brain Aβ dimers were analyzed by WB using 6E10 and 4G8 antibodies, respectively. 
M = monomer, D = dimer. AD = Alzheimer’s disease, Pre-clinical AD = Pre-clinical 
Alzheimer’s disease, NAD = non-Alzheimer’s disease.  
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Figure 4. The presence of CL Aβ dimers in the brains of patients with AD is 
confirmed by bottom-up proteomics. Detection of the trypsin cross-linked peptide 
[Aβ(6-16)]2 in PICUP CL Aβ(1-40) dimers (a-h, top) and brain Aβ dimer samples 
obtained from two distinct AD patients, AD2 (a-d, bottom mirror) and AD1 (e-h, 
bottom mirror). (a, e) Detection of the + 5 charge state of the [Aβ(6-16)]2 peptide as 
the precursor ion, m/z 534.8444. (b, f) Full MS/MS. (c, g) Selection of four 
characteristic MS/MS transitions for the [Aβ(6-16)]2 peptide: b2+ 253.093, y52+ 
324.682, b104+ 631.775, and b63+ 674.949. (d, h) Assignment of the fragment ions 
detected in MS/MS spectra and analyzed by StavroX, on the peptide sequence. 
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